Clinical Trial Update: Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating Famitinib plus SHR-A1811 versus SHR-A1811 alone in CDK4/6 inhibitor–resistant advanced hormone receptor-positive, HER…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Famitinib (Famitinib)
• SHR-A1811

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING